The Court of Appeal in London has ruled in favour of several generic drug manufacturers, dismissing an appeal brought by pharmaceutical giant Gilead in a dispute over...HIV/AIDS
Despite prospective cohort trials not producing evidence of an increased risk of neural tube defects (NTDs) with dolutegravir (DTG), elvitegravir and raltegravir, or...HIV/AIDS
In 2014, ViiV Healthcare, a pharmaceutical company dedicated to ending the HIV epidemic, and the Medicines Patent Pool, an organisation funded primarily by Unitaid to...HIV/AIDS
An implant containing islatravir, which is inserted under the skin of the upper arm, should provide sustained levels of drug sufficient to prevent HIV infection for over...HIV/AIDS
Professor Francois Venter and Dr Simiso Sokhela write in a Spotlight report: “South Africa’s next big shift in our antiretroviral programme is to replace Efavirenz...Weekly Roundup
The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical...Medico-Legal
Pharmaceuticals company Gilead is set to lose intellectual property rights for a drug it developed to treat HIV, freeing other drugs companies to launch generic...
June 13th, 2018The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more...
An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical...Weekly Roundup
A leading Aids researcher and proponent of medication-assisted therapy for addiction has been appointed to oversee the US Centres for Disease Control and Prevention,...
